Autophagie
Les inhibiteurs de l'autophagie ciblent le processus cellulaire de l'autophagie, qui implique la dégradation et le recyclage des composants cellulaires via les lysosomes. L'autophagie est un mécanisme crucial pour maintenir l'homéostasie cellulaire, mais sa dérégulation est impliquée dans diverses maladies, y compris le cancer, les maladies neurodégénératives et les infections. Les inhibiteurs de l'autophagie peuvent bloquer ce processus, ce qui en fait des outils précieux pour étudier le rôle de l'autophagie dans les maladies et développer des stratégies thérapeutiques. Chez CymitQuimica, nous proposons des inhibiteurs de l'autophagie pour soutenir vos recherches en biologie cellulaire, oncologie et maladies neurodégénératives.
1492 produits trouvés pour "Autophagie"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
DC-LC3in-D5
CAS :DC-LC3in-D5 is a potent and selective covalent inhibitor of LC3A/B that disrupts autophagy by covalently binding to Lys49 on LC3B.Formule :C19H22Cl2N2O3Degré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :397.3Ref: TM-T61871
1mg94,00€5mg222,00€10mg356,00€25mg713,00€50mg1.108,00€100mg1.738,00€200mg2.332,00€1mL*10mM (DMSO)245,00€(R,R)-LRRK2-IN-7
CAS :(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.Formule :C24H26N6OMasse moléculaire :414.50Hesperadin hydrochloride
Hesperadin hydrochloride is an ATP-competitive indolone inhibitor of Aurora A and B, with an IC50 value of 250 nM for Aurora B.Formule :C29H33ClN4O3SCouleur et forme :SolidMasse moléculaire :553.12YW3-56 (hydrochloride) (technical grade)
CAS :YW3-56: PAD2 & PAD4 inhibitor (IC50 = 0.5-5 μM), halts U2OS cell growth (IC50 ~2.5 μM), reduces S-180 & MDA-MB-231 tumor growth in mice.Formule :C27H33Cl2N5O2Couleur et forme :SolidMasse moléculaire :530.49HDAC1-IN-8
CAS :HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.Formule :C22H24N2O4Couleur et forme :SolidMasse moléculaire :380.437CXCR2/CCR7 antagonist-1
CAS :CXCR2/CCR7 antagonist-1 (compound 6) is a potent dual antagonist of CXCR2 and CCR7, with IC50 values of 0.0046 μM and 0.0014 μM, respectively. It is valuable for research in tumor metastasis and autoimmune diseases.Formule :C23H27N3O5Couleur et forme :SolidMasse moléculaire :425.48HMG499
CAS :HMG499 inhibits HMG-CoA reductase (IC50: 0.41μM), reduces statin-induced HMGCR, lowers cholesterol, and lessens atherosclerosis.Formule :C33H54O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :498.78SH498
CAS :<p>SH498 is a novel Bmi-1-mediated anti-tumor agent with significant anti-proliferative effects.</p>Formule :C27H25F3N2O4Couleur et forme :SolidMasse moléculaire :498.49CXCR4 antagonist 10
CAS :CXCR4 antagonist10 (compound 21) is an effective CXCR4 inhibitor with an IC50 value of 7.8 nM. It plays a significant role in cancer research.Formule :C18H18N4O4Couleur et forme :SolidMasse moléculaire :354.36LRRK2-IN-20
CAS :LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).Formule :C24H32ClN7OCouleur et forme :SolidMasse moléculaire :470.01HDAC10-IN-1
HDAC10-IN-1 is a potent, selective HDAC10 inhibitor (IC50=58 nM) affecting autophagy in FLT3-ITD+ acute myeloid leukemia cells.Formule :C18H23N3O2Couleur et forme :SolidMasse moléculaire :313.39SW063058
CAS :SW063058 is an autophagy inducer that specifically disrupts the interaction between Beclin 1 and Bcl-2 without affecting the interactions of Bcl-2 with pro-apoptotic members (such as Bax and BIM). By inhibiting the negative regulation of Beclin 1 (key to autophagy initiation) by Bcl-2, SW063058 enhances autophagic activity without inducing cytotoxicity, apoptosis, or other forms of cell death in vitro.Formule :C22H15BrFIN2O2Couleur et forme :SolidMasse moléculaire :565.17HDAC10-IN-2
HDAC10-IN-2, a selective HDAC10 inhibitor (IC50=20nM), modulates autophagy in FLT3-ITD+ acute myeloid leukemia.Formule :C19H22N2O2Couleur et forme :SolidMasse moléculaire :310.39CXCR7 antagonist-1 hydrochloride
CAS :CXCR7 antagonist-1 hydrochloride, Inhibits SDF-1 (CXCL12) or I-TAC binding to CXCR7, used for tumor and inflammation research.Formule :C21H20ClFN6ODegré de pureté :99.84%Couleur et forme :SolidMasse moléculaire :426.874-FPBUA
CAS :4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.Formule :C31H23FO7Couleur et forme :SolidMasse moléculaire :526.51LRRK2-IN-2
CAS :LRRK2-IN-2: selective, potent LRRK2 inhibitor, IC50 of 0.6 nM, oral, crosses blood-brain barrier, for Parkinson's research.Formule :C23H23Cl2F3N6O2Couleur et forme :SolidMasse moléculaire :543.37LRRK2-IN-5
LRRK2-IN-5 is an oral, BBB-penetrating selective inhibitor for LRRK2 with IC50s: 1.2μM (GS) and 16μM (WT); halts LRRK2 autophosphorylation.Formule :C24H26F2N4O2SCouleur et forme :SolidMasse moléculaire :472.55LRRK2-IN-6
LRRK2-IN-6 is an oral, selective LRRK2 inhibitor crossing the blood-brain barrier, targeting GS (IC50: 4.6μM) and WT LRRK2 (IC50: 49μM).Formule :C23H24F2N4O2SCouleur et forme :SolidMasse moléculaire :458.52SCH-900875
CAS :SCH-900875 is an orally active, brain-penetrant, and selective inhibitor of the CXCR3 receptor, demonstrating significant selectivity towards CXCR1 and CXCR2 receptors as well. By binding to CXCR3, SCH-900875 blocks the ligands CXCL9, CXCL10, and CXCL11, thereby inhibiting downstream G protein and β-arrestin signaling pathways and reducing inflammation cell migration. This compound holds potential for research into autoimmune diseases (such as rheumatoid arthritis and multiple sclerosis) and inflammatory conditions (such as psoriasis and inflammatory bowel disease).Formule :C28H37ClN8O2Couleur et forme :SolidMasse moléculaire :553.10LRRK2-IN-19
CAS :LRRK2-IN-19 is a PROTAC-targeted protein ligand utilized in the synthesis of PROTAC JH-XII-03-02. JH-XII-03-02 acts as an effective and selective LRRK2 PROTAC degrader, which is applicable for research in Parkinson's disease.Formule :C19H22N6OCouleur et forme :SolidMasse moléculaire :350.42
